MedTrace Logo

T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade

NCT01060098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2020-01-18

Study results available
· View outcomes & findings →

Summary

We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National Health Service) trusts will be recruited. We will correlate disease activity assessed by clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and target tissues, such as synovium and skin.

Conditions

Interventions

DRUG

anti-TNF therapy (etanercept or adalimumab)

Biological DMARD

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sonya Abraham · Imperial College London

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01060098 on ClinicalTrials.gov